Published in Am J Physiol on June 01, 1997
Animal models of cardiovascular diseases. J Biomed Biotechnol (2011) 1.73
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol (2012) 1.24
Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis (2010) 1.01
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol (2011) 0.96
Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol (2011) 0.91
Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis (2007) 0.88
GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol (2007) 0.87
Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One (2014) 0.84
Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol (2008) 0.83
Predictors of mean arterial pressure morning rate of rise and power function in subjects undergoing ambulatory blood pressure recording. PLoS One (2014) 0.83
The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. Curr Hypertens Rep (2013) 0.81
Fibroblast Angiotensin II Type 1a Receptors Contribute to Angiotensin II-Induced Medial Hyperplasia in the Ascending Aorta. Arterioscler Thromb Vasc Biol (2015) 0.80
Sympathoexcitation associated with Renin-Angiotensin system in metabolic syndrome. Int J Hypertens (2013) 0.79
Characteristic changes in coronary artery at the early hyperglycaemic stage in a rat type 2 diabetes model and the effects of pravastatin. Br J Pharmacol (2009) 0.79
Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol Rep (2014) 0.78
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. J Diabetes Res (2016) 0.78
Why do antioxidants fail to provide clinical benefit? Curr Control Trials Cardiovasc Med (2000) 0.77
Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction. PLoS One (2014) 0.76
Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man. Br J Clin Pharmacol (1998) 0.75
Obesity-Related Hypertension in Children. Front Pediatr (2017) 0.75
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol (1991) 3.60
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol (1991) 2.72
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol (2010) 2.12
Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation (1999) 2.05
Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res (1994) 2.04
Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev (1995) 1.91
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 1.84
Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 1.76
Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation (2000) 1.73
[The cardiovascular risk factor in obesity]. Dtsch Med Wochenschr (2000) 1.73
Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract (2007) 1.69
Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation (1998) 1.69
Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest (2002) 1.67
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation (1999) 1.67
Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res (1994) 1.66
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension (1994) 1.56
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol (2013) 1.55
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation (1996) 1.55
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost (2003) 1.54
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol (2001) 1.51
Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res (1995) 1.51
Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in female pattern hair loss. Br J Dermatol (2012) 1.44
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A (1989) 1.43
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 1.43
[New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr (1997) 1.42
Defining the optimum upper heart rate limit during exercise: a study in pacemaker patients with heart failure. Eur Heart J (2002) 1.41
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 1.41
Xamoterol and the failing heart. Lancet (1989) 1.41
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 1.40
[Atrial fibrillation]. Dtsch Med Wochenschr (2006) 1.39
[Clinical features and current treatment of hypertensive crisis]. Dtsch Med Wochenschr (2003) 1.39
[Alcohol and myocardial infarct. Epidemiological and experimental studies on the effect of alcohol on vascular relaxation and coronary sclerosis]. Dtsch Med Wochenschr (1998) 1.39
[Dissection of the ramus interventricularis anterior in blunt chest trauma]. Dtsch Med Wochenschr (1999) 1.39
[Preoperative cardiovascular risk evaluation--diagnosis]. Dtsch Med Wochenschr (2004) 1.39
[Statins as new therapeutic possibility in osteoporosis?]. Dtsch Med Wochenschr (2001) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension (1991) 1.36
Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res (1999) 1.36
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
The failing human heart is unable to use the Frank-Starling mechanism. Circ Res (1994) 1.31
Purification and chemical characterization of staphyloferrin B, a hydrophilic siderophore from staphylococci. Biometals (1993) 1.31
Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A. Oncogene (2007) 1.28
Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension (1997) 1.26
Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci U S A (1999) 1.25
Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol (2012) 1.24
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation (1997) 1.23
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation (1998) 1.16
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol (2001) 1.16
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens (2009) 1.16
Physician gender is associated with the quality of type 2 diabetes care. J Intern Med (2008) 1.15
Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol (1990) 1.15
Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation (2001) 1.14
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol (1992) 1.14
Evidence for functional relevance of an enhanced expression of the Na(+)-Ca2+ exchanger in failing human myocardium. Circulation (1996) 1.14
Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol (1996) 1.12
Hoe 694, a new Na+/H+ exchange inhibitor and its effects in cardiac ischaemia. Br J Pharmacol (1993) 1.11
Warm water infusion colonoscopy: a review and meta-analysis. Endoscopy (2012) 1.10
Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol (1998) 1.10
Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol (1994) 1.10
Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension (1995) 1.09
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol (1992) 1.09
Prediction of fluid responsiveness in infants and neonates undergoing congenital heart surgery. Br J Anaesth (2011) 1.09
Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost (2004) 1.08
Cardiovascular risk, drugs and erectile function--a systematic analysis. Int J Clin Pract (2011) 1.07
Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol (1996) 1.07
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol (2000) 1.07
Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol (2003) 1.07
What are subcutaneous adipocytes really good for? Exp Dermatol (2007) 1.06
Evidence against spare or uncoupled beta-adrenoceptors in the human heart. Am Heart J (1990) 1.06
Transcatheter closure of secundum atrial septal defects with the new self-centering Amplatzer Septal Occluder. Eur Heart J (1999) 1.05
Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation (2001) 1.05
Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol (2014) 1.04
Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol (2011) 1.02
Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol (2011) 1.02
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol (2009) 1.01
The effect of Gi-protein inactivation on basal, and beta(1)- and beta(2)AR-stimulated contraction of myocytes from transgenic mice overexpressing the beta(2)-adrenoceptor. Br J Pharmacol (2000) 1.01
[Characteristics of patients with coronary ectasias with and without stenotic coronary artery disease]. Dtsch Med Wochenschr (2005) 1.01
Interactions among ACE, kinins and NO. Cardiovasc Res (1999) 1.01
Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol (1997) 1.01
Application of cell culture for the production of bioactive compounds from sponges: synthesis of avarol by primmorphs from Dysidea avara. J Nat Prod (2000) 1.01
The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia. J Cardiovasc Pharmacol (1992) 1.00
Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene (1996) 1.00
Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J Pharmacol Exp Ther (1984) 1.00
Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol (1999) 1.00
Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol (1993) 0.99